Abstract
The majority of newly diagnosed metastatic non-small cell lung cancer (mNSCLC) patients will receive chemotherapy with a single-agent PD1 inhibitor as initial therapy. Combination immunotherapy with PD1-CTLA4 inhibitors either alone or with chemotherapy represent competing alternative treatment strategies. However, there exists a limited understanding of the immunologic factors that predict for preferential response to combination immunotherapy versus chemo-immunotherapy and no definitive biomarkers exist to select patients preferentially for either strategy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
